Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus

Autor: Annels, Nicola E., Arif, Mehreen, Simpson, Guy R., Denyer, Mick, Moller-Levet, Carla, Mansfield, David, Butler, Rachel, Shafren, Darren, Au, Gough, Knowles, Margaret, Harrington, Kevin, Vile, Richard, Melcher, Alan, Pandha, Hardev

Publikováno v: In Molecular Therapy - Oncolytics 29 June 2018 9:1-12

Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21

Autor: Annels, Nicola E, Mansfield, David, Arif, Mehreen, Ballesteros-Merino, Carmen, Simpson, Guy R, Denyer, Mick, Sandhu, Sarbjinder S, Melcher, Alan, Harrington, Kevin J, Davies, BronwYn, Au, Gough, Grose, Mark, Bagwan, Izhar N, Fox, Bernard A., Vile, Richard G, Mostafid, Hugh, Shafren, Darren, Pandha, Hardev

Purpose: The CANON (CAVATAK in NON-muscle invasive bladder cancer) study evaluated a novel ICAM-1-targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. Experimental Design: Fifteen patients enrolled on this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______305::c06ed4a9dbd6a36a3e5f422d0c065f02
https://surrey.eprints-hosting.org/852248/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.

Autor: Annels NE; Targeted Cancer Therapy, Department of Clinical and Experimental Medicine, Leggett Building, University of Surrey, Guildford, Surrey GU2 7WG, UK., Simpson GR; Targeted Cancer Therapy, Department of Clinical and Experimental Medicine, Leggett Building, University of Surrey, Guildford, Surrey GU2 7WG, UK., Denyer M; Targeted Cancer Therapy, Department of Clinical and Experimental Medicine, Leggett Building, University of Surrey, Guildford, Surrey GU2 7WG, UK., Arif M; Targeted Cancer Therapy, Department of Clinical and Experimental Medicine, Leggett Building, University of Surrey, Guildford, Surrey GU2 7WG, UK., Coffey M; Oncolytics Biotech, Inc., 210, 1167 Kensington Crescent NW Calgary, AB T2N 1X7, Canada., Melcher A; Translational Immunotherapy Team, The Institute of Cancer Research, 237 Fulham Road, London SW6 6JB, UK., Harrington K; Targeted Therapy Team, The Institute of Cancer Research, 237 Fulham Road, London SW6 6JB, UK., Vile R; Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA., Pandha H; Targeted Cancer Therapy, Department of Clinical and Experimental Medicine, Leggett Building, University of Surrey, Guildford, Surrey GU2 7WG, UK.

Publikováno v: Molecular therapy oncolytics [Mol Ther Oncolytics] 2020 Oct 04; Vol. 20, pp. 434-446. Date of Electronic Publication: 2020 Oct 04 (Print Publication: 2021).